Subsequently, these proteins might be employed to dis criminate between the leukemic

05 was considered to indicate a statistically significant difference. Results The clinical outcome of patients from the phase II trial has been previously reported, buy INNO-406 Briefly, of the 23 pa tients enrolled in the current study who were evaluable for efficacy after completion two cycles of sunitinib ther apy, one had a confirmed PR and 15 had SD, the other 7 showed PD. In 14 patients PFS 6 months was encountered and the other 9 had PFS 6 months, In addition, 9 of 23 pa tients were categorized as having tumor throm bosis; 5 showed PFS 6 months and the other 4 had PFS 6 months, RECIST, mRECIST, DWI and MRP parameters at baseline and after 2 week of sunitinib therapy in HCC and tumor thrombus The tumor parameters at baseline and 2 week post sunitinib therapy are shown in Table 1.

There was minimal buy Lapatinib change in median tumor burden based on RECIST and mRECIST and median tumor thrombus diameter, There was an increase in median tumor ADC value from 0. 88 × 10 3 mm2 s to 0. 98 × 10 3 mm2 s and in median tumor thrombus ADC value from 0. 89 × 10 3 mm2 s to 1. 02 × 10, In the RR, median baseline RECIST and mRECIST derived tumor burden was 9. 50 cm and 10. 14 cm with a median percent change of 1. 15% and 3 mm2 s, The Ktrans change of HCC in MRP 1. 94%, whereas in the NR the median tumor burden was more substantial with a decrease from median baseline value of 2. 15 min−1 to 2 week post treatment value of 0. 94 min−1, The HCC also showed relatively higher median Kep at baseline and a significant decrease compared with post treatment value, The tumor thrombus displayed similar diffusion and perfusion fea tures as their primary HCC at baseline and after treat ment.

The examples of Ktrans and ADC changes Lonafarnib 構造 in an indexed HCC lesion after sunitinib administration are illustrated in Figures 1 and 2. Correlation of baseline and percent changes in DWI and MRP parameters with clinical outcome For correlation with clinical outcome, patients were di vided into two groups: responders and nonre sponders after completion of 2 cycles of sunitinib therapy in 23 patients. 16 were classified as RR and the remaining 7 as NR was 10. 30 cm with a median percent change of 33. 98% for RECIST and 6. 12 cm with a median percent change of 0. 49%, The median baseline tumor thrombus diameter in RR and NR was 26. 42 mm and 31.

48 mm without any significant change at the end of sunitinib treatment, Likewise, al though the median baseline ADC value was relatively higher in NR, there was no significant difference in the median baseline ADC value as well as the median per cent change of HCC and tumor thrombus between RR and NR. In contrast, Ktrans in RR showed significantly larger median percent change than NR, Similarly, Kep in RR showed significantly larger median percent change than NR, Moreover, the median percent Ktrans change of tumor thrombus in RR was also larger than that in NR, The median baseline as well as the median percent changes of EVF values in HCC and tumor thrombus didnt show any significant difference between RR and NR, Correlation of baseline and percent changes in DWI and MRP parameters at 2 weeks with PFS We then examined the correlation of baseline and per cent changes in DWI and MRP parameters with PFS.